|
Bone markers |
|||||||||
| Placebo |
Simvastatin 20 |
Simvastatin 40 |
|||||||
| Baseline |
6 weeks |
12 weeks |
Baseline |
6 weeks |
12 weeks |
Baseline |
6 weeks |
12 weeks |
|
|
|
|||||||||
| NTX-I, nM BCE |
15.5 ± 1.8 |
15.7 ± 2.0 |
15.9 ± 1.4 |
16.5 ± 1.7 |
15.9 ± 1.2 |
19.6 ± 1.8 |
19.3 ± 2.4 |
17.6 ± 2.1 |
18.1 ± 2.0 |
| CTX-I, ng/ml |
95.4 ± 5.9 |
86.4 ± 7.9 |
86.9 ± 11.5 |
90.3 ± 10.1 |
83.2 ± 12.1 |
107.2 ± 18.8 |
108.2 ± 11.3 |
94.2 ± 14.1 |
120.7 ± 12.2 |
| Bone ALP, U/L |
14.3 ± 2.4 |
14.0 ± 2.5 |
14.4 ± 2.9 |
19.0 ± 3.0 |
17.4 ± 2.8 |
17.2 ± 2.8 |
14.3 ± 2.2 |
13.4 ± 2.2 |
14.0 ± 2.2 |
|
Mean + SE | |||||||||
Hsia et al. BMC Musculoskeletal Disorders 2002 3:7 doi:10.1186/1471-2474-3-7 |
|||||||||